ODM-201
| Price | $2 |
| Package | 1kg |
| Min. Order: | 1kg |
| Supply Ability: | 100kg |
| Update Time: | 2019-07-06 |
Product Details
| Product Name: ODM-201 | CAS No.: 1297538-32-9 |
| Min. Order: 1kg | Purity: 99% |
| Supply Ability: 100kg | Release date: 2019/07/06 |
| Product NUmber: : WM.562 |
| ODM-201 Basic information |
| Product Name: | ODM-201 |
| Synonyms: | ODM-201;BAY-1841788;N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide;N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide (ODM-201) |
| CAS: | 1297538-32-9 |
| MF: | C19H19ClN6O2 |
| MW: | 398.84616 |
| EINECS: | -0 |
| Product Categories: | |
| Mol File: | 1297538-32-9.mol |
 |
|
| ODM-201 Chemical Properties |
| Safety Information |
| MSDS Information |
| ODM-201 Usage And Synthesis |
| Description | ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies. |
| References | Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007. Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013. Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85. |
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1000.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-05 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-05 | ||
| $485.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $45.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | |
| $40.00 |
VIP4Y
|
Hebei Dangtong Import and export Co LTD
|
2026-02-25 | |
|
VIP3Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2026-01-19 | ||
| $285.00 |
Wuhan Nutra Biotechnology Co.,Ltd
|
2024-11-01 | ||
| $9.00 |
Hebei Kangcang new material Technology Co., LTD
|
2024-05-11 | ||
| $25.00 |
Anhui Ruihan Technology Co., Ltd
|
2023-08-22 | ||
| $100.00 |
Henan Bao Enluo International TradeCo.，LTD
|
2023-07-19 |
China- Since: 2014-12-17
- Address: Zhengzhou High tech Zone, Henan Province, China
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com